Plasma neurofilament light chain levels in Alzheimer’s disease
Open accessAbstract
Plasma neurofilament light (NFL) levels may be a marker of neuronal injury. We examined whether plasma NFL might be a potential biomarker for the prodromal and dementia stages of AD. Participants included 193 cognitively normal (CN), 198 amnestic mild cognitive impairment (aMCI) and 187 Alzheimer's disease (AD) individuals enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Plasma NFL levels were examined by the Single Molecule array (Simoa) technique. Our results showed significantly increased plasma NFL levels in both AD (50.9pg/ml) and aMCI (43.0pg/ml) groups compared to CN (34.7pg/ml) group (both p<0.001), but with substantial overlap between the groups. Plasma NFL levels in AD group was also markedly increased, compared with aMCI group (p<0.001). Plasma NFL levels were positively associated with age (r=0.355, p<0.001) and negatively with global cognition (r=-0.355, p<0.001) in all subjects. Our results suggest that plasma NFL levels may not be a useful biomarker for the diagnosis of prodromal and dementia stages of AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Few longitudinal NfL studies exist, and it is still uncertain how useful NfL is as a biomarker before neurodegenerative symptoms begin.
“However, longitudinal analyses are largely missing and the importance of NfL as a molecular biomarker for the presymptomatic phase of neurodegenerative diseases remains unclear6,9,17.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · see citing works
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J. H., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 486 · see citing works
Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481 · see citing works
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435 · see citing works
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I., Dick, K. M., Brotherhood, E., Gordón, E., Fellows, A. D., Toombs, J., Druyeh, R., Cardoso, M. J., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 431 · see citing works
Neurochemical Aftermath of Amateur Boxing
Zetterberg, H., Hietala, M. A., Jonsson, M. A. G., Andreasen, N., Styrud, E., Karlsson, I., Edman, Å., Popa, C., Rasulzada, A., Wahlund, L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1277 · Cited by 355 · see citing works
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · see citing works
Kuhle, J., Barro, C., Disanto, G., Mathias, A., Soneson, C., Bonnier, G., Yaldizli, Ö., Regeniter, A., Derfuss, T., Canales, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515623365 · Cited by 257 · see citing works
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
Kühle, J., Gaiottino, J., Leppert, D., Petzold, A., Bestwick, J., Malaspina, A., Lu, C., Dobson, R., Disanto, G., Norgren, N., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307454 · Cited by 197 · see citing works
Vågberg, M., Norgren, N., Dring, A. M., Lindqvist, T., Birgander, R., Zetterberg, H., & Svenningsson, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135886 · Cited by 141 · see citing works
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
Disanto, G., Adiutori, R., Dobson, R., Martinelli, V., Costa, G. D., Runia, T. F., Evdoshenko, E. P., Thouvenot, É., Trojano, M., Norgren, N., et al. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309690 · Cited by 141 · see citing works
A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
Petzold, A., Keir, G., Warren, J. D., Fox, N. C., & Rossor, M. N. (2007) · Neurodegenerative Diseases · doi:10.1159/000101843 · Cited by 112 · see citing works
Hu, Y., Shanshu, H., Wang, X., Duan, Q., Khatoon, S., Iqbal, K., Grundke, I., & Wang, J. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00047-2 · Cited by 106 · see citing works
Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke
Hjalmarsson, C., Bjerke, M., Andersson, B., Blennow, K., Zetterberg, H., Åberg, N. D., Olsson, B., Eckerström, C., Bokemark, L., & Wallin, A. (2014) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s13821 · Cited by 94 · see citing works
CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults
Idland, A., Sala‐Llonch, R., Borza, T., Watne, L. O., Wyller, T. B., Brækhus, A., Zetterberg, H., Blennow, K., Walhovd, K. B., & Fjell, A. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.012 · Cited by 76 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · see citing works
Self-citationDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · see citing works
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · see citing works
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345 · see citing works
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258 · see citing works
Pontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3392 · Cited by 261 · see citing works
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177 · see citing works
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142 · see citing works
Clark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T. K., Blennow, K., Zetterberg, H., & Popp, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00805-8 · Cited by 88 · see citing works
- Authors
- Zhou, W., Zhang, J., Ye, F., Xu, G., Su, H., Su, Y., & Zhang, X.
- Affiliations
- Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Hangzhou Normal University (CN)
- Peking University (CN)
- Corresponding author
- Zhang, Jie
- Zhang, Xiangyang
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 650
- Pages
- 60-64
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2606815270
- Cited by
- 95
- References
- 16
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 11 · 2021: 14 · 2020: 18 · 2019: 9 · 2018: 11 · 2017: 2
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 354 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Neuroscience Letters (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer’s Disease Neuroimaging Initiative (U01 AG024904)
- DOD ADNI (W81XWH-12-2-0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie, Alzheimer’s Association
- Alzheimer’s Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity; Lundbeck; Merck & Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma neurofilament light chain, Alzheimer's disease, amnestic mild cognitive impairment, biomarkers, neuronal injury, prodromal Alzheimer's disease, dementia, cognitive decline, global cognition
- MeSH terms
- Aged, Alzheimer Disease, China, Dementia, Diagnosis, Differential, Female, Humans, Male, Risk Factors, Sensitivity and Specificity, Reproducibility of Results, Biomarkers, Comorbidity, Causality, Prevalence, Neurofilament Proteins, Cognitive Dysfunction, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
